BeyondBio Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Yuseong Korea, Republic of (2013)

Organization Overview

First Clinical Trial
2018
NCT03579836
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BeyondBio Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

bey1107 (3 trials)

capecitabine (xeloda) (1 trial)

gemcitabine (gemzar) (1 trial)

Drugs in Phase 1 Trials (2)

bey2153 (1 trial)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 5